Zimmer Biomet Holdings, Inc. (ZBH) Stock Analysis and Metrics

Zimmer Biomet Holdings

NYSE: ZBH

$91.35 ▲ +1.70 (+1.90%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap17.48 Bn

P/E-88.53

P/S2.08

Div. Yield0.01

ROIC (Qtr)0.01

Total Debt (Qtr)7.47 Bn

Revenue Growth (1y) (Qtr)9.30

Add ratio to table…

About

Zimmer Biomet Holdings, Inc. is a global medical technology company that designs manufactures and markets products for musculoskeletal health. The company focuses on orthopedic reconstructive implants sports medicine biologics extremities trauma craniomaxillofacial and thoracic devices bone cement surgical tools and integrated digital and robotic platforms. It works with healthcare professionals worldwide to improve patient mobility and quality of life.

Zimmer Biomet Holdings Inc. generates revenue primarily through the sale of its orthopedic and related medical devices. Its product portfolio includes knee and hip replacement systems sports medicine and soft tissue repair products biologics extremities and trauma offerings craniomaxillofacial and thoracic implants bone cement surgical instruments and a suite of digital robotic and data analytics solutions. The company sells these products to orthopedic surgeons neurosurgeons hospitals ambulatory surgery centers stocking distributors healthcare dealers and group purchasing organizations. Revenue is recognized when title transfers to the customer either upon shipment or under consignment arrangements where inventory remains under the companys title until used in a procedure.

Zimmer Biomet Holdings Inc. holds a leading position in the global orthopedics market alongside major competitors such as Johnson Johnson MedTech Stryker Corporation and Smith Nephew plc. The companys competitive advantages stem from its broad and integrated product suite its investment in research and development and its strong global distribution network. Its ability to offer combined surgical robotic and digital technologies through the ZBEdge platform further differentiates it from peers. Continuous innovation in materials implant design and surface technologies supports its market standing.

Zimmer Biomet Holdings Inc. serves a diverse customer base that includes orthopedic surgeons neurosurgeons hospitals ambulatory surgery centers and other specialist physicians. It also sells through stocking distributors healthcare dealers and group purchasing organizations that act as buying agents for healthcare institutions. No single customer accounted for more than two percent of net sales in the most recent fiscal year indicating a widely diversified client base.

Investment Thesis

▲ Bull case

Zimmer Biomet's transformation of its U.S. sales force toward a dedicated and specialized channel is yielding early signs of substantial productivity gains that the market is not fully appreciating. The company reported a reduction in non-dedicated 1099 representatives from approximately 66% at the start of 2026 to below 60% by the end of Q1, indicating a meaningful shift toward exclusivity. In territories where this transition has been implemented, case productivity has jumped from an average of 7 cases per week to double-digit ranges, directly correlating with increased sales effectiveness. This structural change is expected to drive sustained acceleration in U.S. sales growth beyond the current 1%-3% organic guidance range as the rollout continues through 2027, particularly benefiting high-margin technology and implant franchises like ROSA and Persona. The market appears to be underestimating the long-term operating leverage from this sales force reorganization, which should improve commercial efficiency and support margin expansion as the company laps the initial disruption phase.
The pipeline of innovative technology products, particularly the Monogram semi-autonomous and fully autonomous robotic systems, represents a significant hidden catalyst that management did not emphasize enough during the call. Zimmer Biomet completed enrollment in its 102-patient clinical study for Monogram and remains on track for U.S. approval and launch of the semi-autonomous version in early 2027, followed by the fully autonomous version in late 2027 or early 2028. The company is proactively investing in this launch by planning to hire over 200 robotic clinical sales representatives by the end of 2027, signaling strong conviction in the product's market potential. Monogram's ability to perform procedures in under 4 minutes with high safety, reproducibility, and accuracy could democratize advanced orthopedic care and create a durable competitive advantage, especially when integrated with the existing ROSA and TMINI platforms. This innovation pipeline is positioned to reaccelerate technology sales growth, which already surged nearly 12% in Q1, and could drive multiple years of above-market growth as adoption scales.
Zimmer Biomet's strategic diversification through acquisitions like Paragon 28 and OrthoGrid is showing stronger-than-expected momentum, with Paragon 28 accelerating to double-digit growth trends and OrthoGrid delivering its strongest quarter to date. The company noted that Paragon 28's first-quarter growth accelerated around 200 basis points from Q4 2025 and is trending back toward double-digit performance, driven by focused investment behind the platform. OrthoGrid's accelerated adoption is solidifying its role as a core driver of the digital ecosystem and interior hip triple play, which now represents nearly 40% of U.S. hip temps. These businesses are not only contributing to top-line growth but are also enhancing the company's value proposition in high-growth segments like sports medicine and digital surgery. The market may be overlooking how these acquisitions are de-risking the legacy reconstructive business and providing complementary growth engines that could sustain organic expansion even if core knee and hip markets face temporary headwinds.

Zimmer Biomet's transformation of its U.S. sales force toward a dedicated and specialized channel is yielding early signs of substantial productivity gains that the market is not fully appreciating. The company reported a reduction in non-dedicated 1099 representatives from approximately 66% at the start of 2026 to below 60% by the end of Q1, indicating a meaningful shift toward exclusivity. In territories where this transition has been implemented, case productivity has jumped from an average of 7 cases per week to double-digit ranges, directly correlating with increased sales effectiveness. This structural change is expected to drive sustained acceleration in U.S. sales growth beyond the current 1%-3% organic guidance range as the rollout continues through 2027, particularly benefiting high-margin technology and implant franchises like ROSA and Persona. The market appears to be underestimating the long-term operating leverage from this sales force reorganization, which should improve commercial efficiency and support margin expansion as the company laps the initial disruption phase.
The pipeline of innovative technology products, particularly the Monogram semi-autonomous and fully autonomous robotic systems, represents a significant hidden catalyst that management did not emphasize enough during the call. Zimmer Biomet completed enrollment in its 102-patient clinical study for Monogram and remains on track for U.S. approval and launch of the semi-autonomous version in early 2027, followed by the fully autonomous version in late 2027 or early 2028. The company is proactively investing in this launch by planning to hire over 200 robotic clinical sales representatives by the end of 2027, signaling strong conviction in the product's market potential. Monogram's ability to perform procedures in under 4 minutes with high safety, reproducibility, and accuracy could democratize advanced orthopedic care and create a durable competitive advantage, especially when integrated with the existing ROSA and TMINI platforms. This innovation pipeline is positioned to reaccelerate technology sales growth, which already surged nearly 12% in Q1, and could drive multiple years of above-market growth as adoption scales.
Zimmer Biomet's strategic diversification through acquisitions like Paragon 28 and OrthoGrid is showing stronger-than-expected momentum, with Paragon 28 accelerating to double-digit growth trends and OrthoGrid delivering its strongest quarter to date. The company noted that Paragon 28's first-quarter growth accelerated around 200 basis points from Q4 2025 and is trending back toward double-digit performance, driven by focused investment behind the platform. OrthoGrid's accelerated adoption is solidifying its role as a core driver of the digital ecosystem and interior hip triple play, which now represents nearly 40% of U.S. hip temps. These businesses are not only contributing to top-line growth but are also enhancing the company's value proposition in high-growth segments like sports medicine and digital surgery. The market may be overlooking how these acquisitions are de-risking the legacy reconstructive business and providing complementary growth engines that could sustain organic expansion even if core knee and hip markets face temporary headwinds.

▼ Bear case

Zimmer Biomet's U.S. knee business continues to face structural challenges that are being masked by short-term tailwinds, and the market may be ignoring the longevity of these headwinds. U.S. knee growth was only 2.2% in Q1, partially offset by pressure in legacy Toran Knee implants such as NextGen and Vanguard, which the company is phasing out as part of its brand rationalization strategy. While the Oxford Partial Cementless Knee drove a greater than 20% increase in partial knee cells, this growth is coming from a smaller base and may not be sufficient to offset declines in total knee procedures. The company acknowledged that U.S. knee comps will get 400 basis points tougher in the back half of the year, yet it offered no concrete evidence that new product adoption or sales force changes will accelerate growth enough to overcome this. The reliance on partial knees as a growth driver raises concerns about market size limitations and long-term sustainability, especially if the shift toward outpatient procedures continues to favor smaller, less invasive interventions that may not fully capitalize on Zimmer Biomet's implant portfolio.
The company's go-to-market transformation, while progressing as planned, is creating ongoing execution risks that could delay the realization of anticipated benefits and weigh on near-term performance. Management admitted to losing two large accounts in Q1 due to the sales force changes, including disruption from a Kaiser strike on the West Coast where Zimmer Biomet had its highest knee share. Although the company expects to recoup some of this business, the acknowledgment of account loss highlights the vulnerability of the transition period. Furthermore, the CFO noted that increased commercial investments in the sales force model are partially offsetting earnings gains, and these costs are not being excluded from non-GAAP metrics. With the transition not expected to complete until the end of 2027, the company faces multiple years of potential disruption, including turnover risks among sales representatives who are being offered 2- to 3-year guarantees but may still leave once those guarantees expire if long-term career prospects are not perceived as strong. This prolonged transition could keep operating expenses elevated and delay margin improvement.
International performance remains a persistent drag on overall growth, with international sales increasing only 2.5% in Q1 despite healthy end markets, and management offered limited clarity on when this segment will meaningfully accelerate. The company cited difficult comps in the first half of the year, distributor changes in emerging markets, Middle East, Europe, and China, and one-time order delays as factors behind the softness. While management expects international mid-single-digit growth in the second half, this outlook appears contingent on the successful execution of distributor consolidation efforts, which have historically caused disruption. The lack of tangible progress in key international markets, combined with the company's reliance on international for geographic diversification, raises concerns that international could remain a growth inhibitor for an extended period. If international fails to reaccelerate as expected, it could offset gains from U.S. sales force productivity and technology adoption, keeping overall organic growth anchored near the lower end of the guidance range.

Zimmer Biomet's U.S. knee business continues to face structural challenges that are being masked by short-term tailwinds, and the market may be ignoring the longevity of these headwinds. U.S. knee growth was only 2.2% in Q1, partially offset by pressure in legacy Toran Knee implants such as NextGen and Vanguard, which the company is phasing out as part of its brand rationalization strategy. While the Oxford Partial Cementless Knee drove a greater than 20% increase in partial knee cells, this growth is coming from a smaller base and may not be sufficient to offset declines in total knee procedures. The company acknowledged that U.S. knee comps will get 400 basis points tougher in the back half of the year, yet it offered no concrete evidence that new product adoption or sales force changes will accelerate growth enough to overcome this. The reliance on partial knees as a growth driver raises concerns about market size limitations and long-term sustainability, especially if the shift toward outpatient procedures continues to favor smaller, less invasive interventions that may not fully capitalize on Zimmer Biomet's implant portfolio.
The company's go-to-market transformation, while progressing as planned, is creating ongoing execution risks that could delay the realization of anticipated benefits and weigh on near-term performance. Management admitted to losing two large accounts in Q1 due to the sales force changes, including disruption from a Kaiser strike on the West Coast where Zimmer Biomet had its highest knee share. Although the company expects to recoup some of this business, the acknowledgment of account loss highlights the vulnerability of the transition period. Furthermore, the CFO noted that increased commercial investments in the sales force model are partially offsetting earnings gains, and these costs are not being excluded from non-GAAP metrics. With the transition not expected to complete until the end of 2027, the company faces multiple years of potential disruption, including turnover risks among sales representatives who are being offered 2- to 3-year guarantees but may still leave once those guarantees expire if long-term career prospects are not perceived as strong. This prolonged transition could keep operating expenses elevated and delay margin improvement.
International performance remains a persistent drag on overall growth, with international sales increasing only 2.5% in Q1 despite healthy end markets, and management offered limited clarity on when this segment will meaningfully accelerate. The company cited difficult comps in the first half of the year, distributor changes in emerging markets, Middle East, Europe, and China, and one-time order delays as factors behind the softness. While management expects international mid-single-digit growth in the second half, this outlook appears contingent on the successful execution of distributor consolidation efforts, which have historically caused disruption. The lack of tangible progress in key international markets, combined with the company's reliance on international for geographic diversification, raises concerns that international could remain a growth inhibitor for an extended period. If international fails to reaccelerate as expected, it could offset gains from U.S. sales force productivity and technology adoption, keeping overall organic growth anchored near the lower end of the guidance range.

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password